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Aims In this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose
reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses
of enalapril.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
In a post-hoc analysis from PARADIGM-HF, we characterized patients by whether they received the maximal dose
(200mg sacubitril/valsartan or 10mg enalapril twice daily) throughout the trial or had any dose reduction to lower
doses (100/50/0mg sacubitril/valsartan or 5/2.5/0mg enalapril twice daily). The treatment effect for the primary
outcome was estimated, stratified by dose level using time-updated Cox regression models. In the two treatment
arms, participants with a dose reduction (43% of those randomized to enalapril and 42% of those randomized to
sacubitril/valsartan) had similar baseline characteristics and similar baseline predictors of the need for dose reduction.
In a time-updated analysis, any dose reduction was associated with a higher subsequent risk of the primary event
[hazard ratio (HR) 2.5, 95% confidence interval (CI) 2.2–2.7]. However, the treatment benefit of sacubitril/valsartan
over enalapril following a dose reduction was similar (HR 0.80, 95% CI 0.70–0.93, P < 0.001) to that observed in
patients who had not experienced any dose reduction (HR 0.79, 95% CI 0.71–0.88, P < 0.001).
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Conclusions In PARADIGM-HF, study medication dose reduction identified patients at higher risk of a major cardiovascular event.
The magnitude of benefit for patients on lower doses of sacubitril/valsartan relative to those on lower doses of
enalapril was similar to that of patients who remained on target doses of both drugs.
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Introduction
In the Prospective Comparison of ARNI with ACEI to Deter-
mine Impact on Global Mortality and Morbidity in Heart Failure
(PARADIGM-HF) trial, sacubitril/valsartan (LCZ696) reduced the
risk of cardiovascular death and of heart failure hospitalization
compared with enalapril in patients with chronic heart failure.1
Sacubitril/valsartan, a complex containing the neprilysin inhibitor
sacubitril and the ARB valsartan, augments endogenous compen-
satory vasoactive peptides by inhibiting their breakdown, and, in
addition, blocks the renin–angiotensin system.2 The active run-in
phase ensured all patients were titrated to a target dose of enalapril
10mg twice daily and then sacubitril/valsartan 200mg twice daily
before randomization. The majority of patients remained on tar-
get doses after randomization, with final mean achieved doses of
375mg daily and 18.9mg daily respectively.1 Nevertheless, not all
patients were maintained on target doses of study medication dur-
ing long-term follow-up. Whether sacubitril/valsartan confers ben-
efit at lower than target doses similar to those taking lower than
target doses of enalapril is unknown.
We utilized data from PARADIGM-HF to test the hypothesis
that participants who exhibited any dose reduction during the trial
would have similar benefits from lower doses of sacubitril/valsartan
relative to lower doses of enalapril.
Methods
Study design and patient selection
PARADIGM-HF was a double-blind, randomized, active controlled trial
designed to assess the impact of the angiotensin receptor neprilysin
inhibitor sacubitril/valsartan compared with enalapril on cardiovascu-
lar mortality and heart failure hospitalizations in patients with LVEF
≤40% and NYHA functional class II–IV heart failure. The protocol was
approved at each participating site by an ethics committee or institu-
tional review board. All participants provided written informed consent
in accordance with established guidelines for the protection of human
subjects.
Eligible subjects had at least mildly elevated natriuretic peptide lev-
els and were treated with stable doses of ACE inhibitors or ARBs
and beta-adrenergic receptor blockers for at least 4 weeks prior to
trial enrolment. Patients with symptomatic hypotension, estimated
glomerular filtration rate (eGFR) <30mL/min/1.73m2, potassium con-
centration >5.2mmol/L at screening, or history of angioedema were
excluded. The study design and detailed inclusion and exclusion criteria
have been previously reported.3
Participants underwent sequential single-blind run-in phases with
enalapril at a dose of at least 10mg twice daily for 2 weeks, followed
by sacubitril/valsartan, first dosed at 100mg twice daily, then 200mg
twice daily for 4–6 weeks. They were then randomized to receive
enalapril 10mg twice daily or sacubitril/valsartan 200mg twice daily,
and were followed for a median duration of 27 months. During
the double-blind phase of the study, investigators were allowed to
down-titrate study drug to one of three lower study medication dose
levels that corresponded to 100mg sacubitril/valsartan twice daily or
5mg enalapril twice daily (dose level 2), or 50mg sacubitril/valsartan
twice daily or 2.5mg enalapril twice daily (dose level 1). Patients could
also discontinue study medication, temporarily, or permanently (dose ..
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.. level zero). At the time of dose reduction, study personnel recorded
information regarding the reason for study medication dosage change
on case report forms.
Statistical analyses
Participants were categorized according to whether or not they
received the target dose of study drug for the entire duration of the
double-blind portion of follow-up. Baseline characteristics were com-
pared between participants who experienced a study medication dose
reduction vs. those who were maintained on target study medication
doses throughout the duration of the study regardless of treatment
assignment. Characteristics were also compared among participants
with a dose reduction between treatment arms. Between-group assess-
ments were performed using t-tests for continuous variables, and 𝜒2
or Fisher’s exact tests, as appropriate, for categorical variables.
We constructed two time-updated covariates: the first
time-updated covariate indicated any prior dose reduction, updated
when a dose change occurred from the maximum dose to any other
lower dose level, and was used to distinguish those patients with
sustained maximum dosage from patients with any reduction in dose.
The second time-updated covariate represented ‘cumulative average’
dose received, updated daily after randomization. Risk factors for the
likelihood of receiving subtarget dosage at any point during follow-up
were determined with a forward stepwise selection process using
the following baseline characteristics: age, sex, geographic region,
body mass index, NT-proBNP, EF, eGFR, NYHA functional class,
history of diabetes mellitus, myocardial infarction, and use of ACE
inhibitors or ARBs, beta-adrenergic blockers, mineralocorticoid
receptor antagonists, and diuretics at screening. Potential interactions
between predictors of dose reduction and treatment assignment were
investigated by using a stepwise selection process separately for each
treatment group. Treatment covariate interaction terms were created
for all covariates found to be significant in either treatment arm, and
interaction terms were considered to be significant if they could be
added to the base model with a P-value <0.05. To investigate the
relationship between dose reduction status and the effectiveness of
sacubtril/valsartan compared with enalapril, the hazard ratio (HR)
for sacubitril/valsartan relative to enalapril for the primary outcome
was estimated, censored at dose reduction, and separately starting
after dose reduction. A sensitivity analysis was performed to examine
effectiveness of sacubitril/valsartan compared with enalapril that
focused on events occurring at least 30 days following dose reduction.
To investigate the relationship between study medication dose levels
and the effectiveness of sacubitril/valsartan compared with enalapril,
time-updated Cox proportional hazards regression models were used
stratified by dose levels. We further assessed the occurrence of dose
reduction by geographic region, and whether any differences were
found in the treatment effect subsequent to dose reductions by region.
A P-value of <0.05 was considered statistically significant. All analyses
were completed using Stata, version 13 (StataCorp LP, College Station,
TX, USA).
Results
Out of 8399 participants in the PARADIGM-HF trial, >99.9% in
both arms achieved the target dose after randomization. In an
intent to treat analysis, 43% of patients in the enalapril arm and 42%
of patients in the sacubitril/valsartan arm reduced their dose at any
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Baseline characteristics by dose reduction status
Characteristic Any dose reduction (n= 3549) No dose reduction (n= 4850) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Baseline age, years 65±12 63±11 <0.001
Female sex (%) 764 (21.5%) 1068 (22.0%) 0.59
Caucasian (%) 2406 (67.8%) 3138 (64.7%) 0.003
Baseline BMI, kg/m2 28.2± 5.6 28.2± 5.5 0.86
NYHA class <0.001
Class I 139 (3.9%) 250 (5.2%)
Class II 2454 (69.3%) 3465 (71.5%)
Class III 929 (26.2%) 1089 (22.5%)
Class IV 20 (0.6%) 40 (0.8%)
Left ventricular ejection fraction (%) 29.4± 6.5 29.5± 6.0 0.49
Ischaemic aetiology (%) 2208 (62.2%) 2828 (58.3%) <0.001
History of hypertension (%) 2528 (71.2%) 3412 (70.4%) 0.38
History of DM (%) 1332 (37.5%) 1575 (32.5%) <0.001
Prior use of ACE inhibitor (%) 2729 (76.9%) 3803 (78.4%) 0.10
Systolic BP, mmHg 120.7±15.8 121.9±14.9 <0.001
Heart rate (b.p.m.) 72.7± 12.4 72.1±11.7 0.035
Serum creatinine, mg/dL 1.18± 0.32 1.08± 0.27 <0.001
NT-proBNP, pg/mL (IQR) 1833 (976, 3834) 1473 (834, 2877) <0.001
Current medications
Diuretics 2912 (82.1%) 3826 (78.9%) <0.001
Beta-blockers 3262 (91.9%) 4549 (93.8%) <0.001
MRA 1918 (54.0%) 2753 (56.8%) 0.013
Digoxin 1077 (30.3%) 1462 (30.1%) 0.84
ICD 657 (18.5%) 586 (12.1%) <0.001
CRT 312 (8.8%) 262 (5.4%) <0.001
BMI, body mass index; BP, blood pressure; DM, diabetes mellitus; ICD, implantable cardioverter defibrillator; IQR, interquartile range; MRA, mineralocorticoid receptor
antagonist.
time after randomization (P= 0.53). Median time to dose reduc-
tion was 255 days [interquartile range (IQR) 70, 516] for enalapril
vs. 249 days (IQR 64, 506) for sacubitril/valsartan (P= 0.54). Of
those with a dose reduction, 1332 (37.5%) subsequently returned
to target study medication doses, and this occurred more fre-
quently in patients randomized to sacubitril/valsartan than with
enalapril (39.8% vs. 35.3%, P= 0.005). Individuals in both groups
who experienced a dose reduction (Table 1) were older, had
worse NYHA functional class, and higher serum creatinine lev-
els and NT-proBNP concentrations at baseline. These partic-
ipants were also more likely to be taking diuretics and have
implantable cardioverter defibrillators or CRT devices. The fre-
quency of dose reduction varied by region (Supplementary mate-
rial online, Table S1), such that dose reductions were most
frequently seen in North America and least observed in Asia.
Among those with a dose reduction, there were no significant
differences in baseline characteristics by treatment assignment
(Table 2).
In a multivariable regression model, many significant predictors
of dose reduction were identified, including: higher serum cre-
atinine, geographic region (North America, Latin America, and
Western Europe), higher NT-proBNP, higher heart rate, older age,
and lower systolic blood pressure (Table 3). There was no signifi-
cant misspecification (P= 0.12), and the associated area under the
curve (AUC) was 0.64. Of 11 statistically significant predictors, .
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.. one nominal interaction with randomized treatment was identi-
fied, in which history of myocardial infarction (MI) was a stronger
predictor of dose reduction in the patients randomized to LCZ696
[odds ratio (OR)= 1.31] than in those randomized to enalapril
(OR=1.06, P for interaction= 0.021). In an analysis of 7156 study
participants with available data of ACE inhibitor or ARB doses at
the time of screening, there was no interaction between dose at
screening and randomized treatment arm with respect to subse-
quent dose reduction (P for interaction= 0.26). Reasons reported
by site investigators for dose reductions differed between the sacu-
bitril/valsartan and enalapril arms, with hypotension responsible
for more dose reductions among those taking sacubitril/valsartan,
and cough more common in those randomized to enalapril
(Table 4). A higher proportion of participants in the sacubi-
tril/valsartan group compared with enalapril were re-up-titrated
to target doses of study medication after down-titration for
hypotension or hyperkalaemia. For cough, a similar propor-
tion of participants were re-up-titrated in each treatment arm
(Table 4).
Any dose reduction, regardless of treatment assignment, was
associated with a higher subsequent risk of the primary event
[HR 2.5, 95% confidence interval (CI) 2.2–2.7; Figure 1]. When
the primary outcome events were censored at the time of dose
reduction, participants taking sacubitril/valsartan had fewer events
relative to enalapril prior to dose reduction (HR 0.79, 95% CI
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Baseline characteristics among those with dose reduction, by treatment group
Characteristic Sacubitril/valsartan (n= 1755) Enalapril (n= 1794) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Baseline age, years 65.3± 11.9 65.2±11.2 0.82
Female sex (%) 359 (20.5%) 405 (22.6%) 0.12
Caucasian (%) 1200 (68.4%) 1206 (67.2%) 0.46
Baseline BMI, kg/m2 28.1± 5.8 28.2± 5.4 0.65
NYHA class 0.72
Class I 65 (3.7%) 74 (4.1%)
Class II 1222 (69.9%) 1232 (68.7%)
Class III 454 (26.0%) 475 (26.5%)
Class IV 8 (0.5%) 12 (0.7%)
Left ventricular ejection fraction (%) 29.5± 6.5 29.4± 6.6 0.57
Ischaemic aetiology (%) 1104 (62.9%) 1104 (61.5%) 0.40
History of hypertension (%) 1260 (71.8%) 1268 (70.7%) 0.46
History of DM (%) 661 (37.7%) 671 (37.4%) 0.87
Prior use of ACE inhibitor (%) 1363 (77.7%) 1366 (76.1%) 0.28
Systolic BP, mmHg 120.7±15.8 120.7± 15.8 0.95
Heart rate (b.p.m.) 72.6± 12.5 72.7±12.3 0.89
Serum creatinine, mg/dL 1.18± 0.32 1.18± 0.32 0.74
NT-proBNP, pg/mL (IQR) 1829 (992, 3637) 1839 (966, 3995) 0.93
Current medications
Diuretics 1439 (82.0%) 1473 (82.1%) 0.93
Beta-blockers 1621 (92.4%) 1641 (91.5%) 0.33
MRA 930 (53.0%) 988 (55.1%) 0.21
Digoxin 509 (29.0%) 568 (31.7%) 0.09
ICD 335 (19.1%) 322 (17.9%) 0.38
CRT 165 (9.4%) 147 (8.2%) 0.20
BMI, body mass index; BP, blood pressure; DM, diabetes mellitus; ICD, implantable cardioverter defibrillator; IQR, interquartile range; MRA, mineralocorticoid receptor
antagonist.
0.71–0.88; Figure 2A). In a landmark analysis beginning at the
time of dose reduction, we observed a similar magnitude of
benefit (HR 0.80, 95% CI 0.70–0.93; Figure 2B). Similar results
were observed after adjustment for characteristics reported in
Table 1 (HR 0.80, 95%CI 0.69–0.92). A sensitivity analysis capturing
events beginning 30 days after dose reduction revealed a similar
reduction of events in participants taking sacubitril/valsartan (HR
0.79, 95% CI 0.67–0.92). Likewise, similar results were noted
when the analysis was repeated while censoring participants who
permanently discontinued study medication (unadjusted HR 0.81,
95% CI 0.69–0.95, P= 0.008; adjusted HR 0.82, 95% CI 0.70–0.95,
P= 0.010). The treatment effect subsequent to dose reductions
was not different between regions (P for interaction= 0.20). In
an analysis that considered only patients who experienced an
initial dose reduction but who did not subsequently permanently
discontinue study drug or return to target dose, the association
between sacubitril/valsartan and the primary outcome remained
unchanged (unadjusted HR 0.78, 95% CI 0.65–0.95; adjusted HR
0.81, 95% CI 0.67–0.98). Patients who permanently discontinued
were at lower risk of a primary event in the first 30 days following
discontinuation if they were in the sacubitril/valsartan arm (HR
0.52, 95% CI 0.26–1.05, P= 0.07), that declined subsequent to 30
days (HR 0.84, 95% CI 0.55–1.28, P= 0.42), although there was
no difference between treatment groups for mortality following
discontinuation (HR 0.97, 95% CI 0.74–1.27). .
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Table 3 Multivariable predictors of any study
medication dose reduction
Characteristic OR 95% CI 𝝌2
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Serum creatinine (per mg/dL) 2.38 2.01–2.82 101.8
Age (per 10 years above 60) 1.27 1.19–1.36 53.6
Region (reference=Central Europe) 49.9
North America 1.77 1.46–2.14
Latin America 1.20 1.04–1.38
Western Europe and other 1.25 1.11–1.42
Asia-Pacific 0.90 0.78–1.04
NT-proBNP (per log) 1.16 1.11–1.22 38.6
SBP (per 10mmHg decrease below 120) 1.21 1.13–1.29 34.1
Heart rate (per 10 b.p.m.) 1.09 1.05–1.14 20.6
NYHA (reference=Class II) 12.6
Class I 0.82 0.66–1.03
Class III 1.15 1.03–1.29
Class IV 0.68 0.39–1.20
History of MI 1.17 1.07–1.29 11.2
History of DM 1.17 1.07–1.29 11.0
Beta-blocker 0.76 0.64–0.91 9.4
Sex: female 1.17 1.04–1.32 7.3
CI, confidence interval; DM, diabetes mellitus; OR, odds ratio; MI, myocardial
infarction; SBP, systolic blood pressure.
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Table 4 Reasons for dose reductions and proportion re-uptitrated, by treatment group
Reason for dose reduction Sacubitril/valsartan (n= 1523)a Enalapril (n= 1524) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hyperkalaemia
(proportion re-up-titrated)
102 (6.7%)
61/102 (60%)
124 (8.1%)
70/124 (56%)
0.13
0.61
Hypotension
(proportion re-up-titrated)
330 (21.7%)
118/330 (36%)
248 (16.3%)
67/248 (27%)
<0.001
0.026
Patient request
(proportion re-up titrated)
225 (14.8%)
27/225 (12%)
230 (15.1%)
21/230 (9%)
0.81
0.32
Renal dysfunction
(proportion re-up-titrated)
133 (8.7%)
55/133 (41%)
150 (9.8%)
42/150 (28%)
0.29
0.018
Angioedema (or angioedema-like event)
(proportion re-up-titrated)
6 (0.4%)
5/6 (83%)
4 (0.3%)
3/4 (75%)
0.53
0.75
Cough
(proportion re-up-titrated)
28 (1.8%)
16/28 (57%)
66 (4.3%)
34/66 (52%)
<0.001
0.62
Other
(proportion re-uptitrated)
556 (36.5%)
328/556 (59%)
576 (37.8%)
330/576 (57%)
0.46
0.56
aNumbers excluded participants whose dose reduction led to permanent discontinuation of study medication.
Figure 1 Kaplan–Meier curves showing primary outcome
events by dose reduction status. Participants with a dose reduc-
tion had a higher risk of the primary event compared with those
who remained on full study medication doses.
When the risk for the primary outcome event was examined
by cumulative mean dose level of study medications, those tak-
ing lower mean doses of sacubitril/valsartan had fewer events
compared with participants taking lower mean doses of enalapril
(Figure 3). As such, the relative reduction in events with sacubi-
tril/valsartan compared with enalapril did not differ according to
the cumulative mean dose of study drug received (P for interac-
tion= 0.99). Nearly identical results were found when the less than
target doses of sacubitril/valsartan were compared with less than
target doses of enalapril with respect to cardiovascular death alone.
Discussion
In patients with heart failure and reduced EF enrolled in the
PARADIGM-HF study, we found that dose reductions were .
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. frequent in both study medication groups, and that patients who
required a dose reduction were at higher risk for major cardio-
vascular events than patients who did not have a dose reduction.
Despite reducing the dose, the magnitude of benefit for patients
on lower doses of sacubitril/valsartan relative to those on lower
doses of enalapril was similar to that of patients who remained
on target dose. These data suggest that patients with heart failure
with reduced EF who are unable to tolerate target doses of
sacubitril/valsartan or enalapril still benefit from lower doses of
sacubitril/valsartan compared with lower doses of enalapril.
The design of PARADIGM-HF, which included an active run-in
phase, during which patients were titrated to target doses of each
study medication, ensured that a higher proportion of patients
remained on enalapril 10mg twice daily than in any previous
trial, and that patients in PARADIGM-HF attained the highest
average dose of enalapril of any large trial.4,5 Nevertheless, dose
reductions in PARADIGM-HF were frequent and were associated
with a variety of patient characteristics. More advanced age, lower
systolic blood pressure, more severe symptoms of heart failure,
or greater renal impairment were more common among those
who experienced a dose reduction, suggesting more significant
disease burden or increased frailty, and these factors were similar
between treatment arms, as was time to dose reduction. These
findings are consistent with other studies that have reported
that age and systolic blood pressure were predictors of failing to
achieve target doses of neurohormonal blockers.6–9 In an analysis
of the IMPROVE-HF study, characteristics associated with lower
than target beta-blocker doses included older age, Caucasian
heritage, lower systolic blood pressure, and an ischaemic heart
failure aetiology.6 Older adults with co-morbidities were less likely
to achieve target doses of ACE inhibitors and beta-blockers
in a retrospective cohort study of primary care practices
in the UK.10
We found that the benefit of sacubitril/valsartan relative to
enalapril was maintained even at lower than target doses. In the
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 (A) Kaplan–Meier curves showing primary outcome events censored at dose reduction by treatment assignment. Individuals taking
sacubitril/valsartan had fewer events compared with the enalapril group [hazard ratio (HR) 0.79, 95% confidence interval (CI) 0.71–0.88].
(B) Kaplan–Meier curves showing primary outcome events following dose reduction by treatment assignment. Individuals randomized to
sacubitril/valsartan had fewer events relative to enalapril after dose reduction (HR 0.80, 95% CI 0.70–0.93).
Figure 3 Hazard ratios (HR; sacubitril/valsartan relative to
enalapril) of the primary outcome measure by time-updated mean
dose post-randomization. Participants taking lower than target
sacubitril/valsartan doses had a lower risk of the primary event
compared with those taking lower than target doses of enalapril.
CI, confidence interval.
Metoprolol CR/XL Randomized Intervention Trial in Heart failure
(MERIT-HF), patients unable to achieve target doses of metopro-
lol had a higher event rate but a similar benefit from beta-blockade
compared with patients who were successfully titrated to target
doses.11 In the Carvedilol Or Metoprolol European Trial (COMET)
study, target doses of carvedilol and metoprolol tartrate were
reached in 75% and 78% of participants, respectively. Failure to
achieve target doses was associated with worse outcomes, but the
benefit of carvedilol relative to metoprolol in lowering all-cause
mortality was maintained at lower doses of beta-blocker.12 Data
from several heart failure registries show that despite guideline .
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. recommendations, less than half of patients are treated with tar-
get doses for both ACE inhibitors and beta-blockers.9,13 Thus,
despite the very large number of patients achieving target doses
in PARADIGM-HF, the number of patients who will achieve these
targets in a real-world setting will probably be lower. Neverthe-
less, our data suggest that even if dose reduction is indicated,
sacubitril/valsartan remains effective compared with enalapril at
reducing the composite of cardiovascular death or heart failure
hospitalizations.
This analysis was post-hoc and thus needs to be interpreted
with caution. In particular, our comparison of patients who had
dose reductions was a post-randomization comparison; yet it is
noteworthy that the baseline characteristics of the patients who
underwent a dose reduction in the two treatment arms were
similar. Furthermore, in earlier studies exploring achieved dose,
MERIT-HF and COMET, patients received subtarget doses of the
study medication because they failed to be successfully up-titrated
during the first few weeks of the trial, and, thus, such a failure
may have been a reflection of patient frailty. In the PARADIGM-HF
trial, only patients demonstrated to be able to tolerate target
doses of the study medications could be randomized. Despite
this, a substantial proportion of patients did require dose reduc-
tions following months of sustained treatment. Yet, the reasons
for post-randomization dose reduction in patients taking sacubi-
tril/valsartan or enalapril were similar to the reasons for intoler-
ance of target doses of these drugs during the run-in period. If
dose reduction resulted in any diminution of the advantage of sacu-
bitril/valsartan over enalapril, we found no evidence for this in the
patients studied in the PARADIGM-HF trial.
In conclusion, in patients with heart failure with reduced EF
enrolled in the PARADIGM-HF trial, dose reductions of study
medications were frequent, but the efficacy of sacubitril/valsartan
relative to enalapril was maintained even among participants taking
© 2016 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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lower doses. These data suggest that patients taking less than
target doses of these drugs would still derive greater benefit from
sacubitril/valsartan when compared with enalapril.
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